A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment

References

• Paulozzi LJ. Prescription drug overdoses: a review. J Safe Res 2012;43:227–326.
   Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the. National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
   Google Scholar
• Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999–2015 on CDC WONDER Online Database, released 2016. Extracted by ONDCP. Available at: http://wonder.cdc.gov/mcd-icd10.html Jan 6, 2016.
   Google Scholar
• Mayet S, Farrell M, Ferri MMF, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2004;4:CD004330.
   Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2008;4:CD005031.
   Google Scholar
• Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend 2011;119:e23–e29.
   PubMedGoogle Scholar
• Crevecoeur-MacPhail D. Whose mu Fared better? The Effect of Extended Release Naltrexone on Treatment Outcomes for Opioid and Alcohol Users. Paper presented at: the 2014 Annual Addiction Health Services Research (AHSR) Conference; October 15-17, 2014; Boston, MA.
   Google Scholar
• Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O’Brien CP. Injectable, sustained- release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210–218.
   PubMed Web of Science ®Google Scholar
• Day E, Strang J. Outpatient versus inpatient opioid detoxification: a randomized controlled trial. J Subst Abuse Treat 2011;40:55–66.
   Web of Science ®Google Scholar
• Saxon AJ, Hser Y, Woody G, Ling W. Medication-assisted treatment for opioid addiction: methadone and buprenorphine. J Food Drug Anal 2013;21:S69–S72.
   PubMed Web of Science ®Google Scholar
• Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455–470.
   PubMedGoogle Scholar
• Chawla JM, Pal H, Lal R, Jain R, Schooler N, Balhara YP. Comparison of efficacy between buprenorphine and tramadol in the medically supervised withdrawal of opioid (heroin)-dependent subjects. J Opioid Manage 2013;9:35–41.
   PubMedGoogle Scholar
• Stine SM, Kosten TR. Pharmacologic interventions for opioid dependence. Principles of addiction medicine, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
   Google Scholar
• Ling W, Amass L, Shoptaw Set al., A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid medically supervised withdrawal: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005 Aug;100:1090–1100.
   Google Scholar
• Gowing L, Farell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2014 Mar 31;CD002024.
   Google Scholar
• Ang-Lee K, Oreskovich MR, Saxon AJ, et al. Single dose of 24 milligrams of buprenorphine for heroin detoxification: an open-label study of five inpatients. J Psychoactive Drugs 2006;38:505–512.
   PubMed Web of Science ®Google Scholar
• Makhinson M, Gomez-Makhinson J. A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole. Am Addict 2014;23:475–477.
   PubMed Web of Science ®Google Scholar
• Brigham G, Amass L, Winhusen T, Harrer JM, Pelt A. Using buprenorphine short-term taper to facilitate early treatment engagement. J Subst Abuse Treat 2007;32:349–356.
   PubMed Web of Science ®Google Scholar
• Assadi SM, Hafezi M, Mokri A, Razzaghi EM, Ghaeli P. Opioid medically supervised withdrawal using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. J Subst Abuse Treat 2004;27:75–82.
   PubMed Web of Science ®Google Scholar
• Palmstierna T. Effects of a high-dose fast tapering buprenorphine medically supervised withdrawal program on symptom relief and treatment retention. J Psychoactive Drugs 2004;36:273–277.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 1990;25:73–78.
   PubMed Web of Science ®Google Scholar
• Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid- abusing adults: dose-effects and time-course. Drug Alcohol Depend 2012;1:57–65.
   Web of Science ®Google Scholar
• Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008 Aug;103:1399–1401
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Bisaga A, Nunes EV, O’Connor PG, Kosten T, Opioid WG. Medically supervised withdrawal and Naltrexone Induction Strategies: recommendations for Clinical Practice. Am J Drug Alcohol Abuse 2012 May;38:187–199.
   PubMed Web of Science ®Google Scholar
• Sullivan, M et al, Long-acting injectable naltrexone induction: a randomized trial of outpatient detoxification with naltrexone versus buprenorphine. American Journal of Psychiatry 2017;174:459–467.
   Google Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double- blind, placebo-controlled multicentre randomized trial. Lancet 2011;377:1506–1513.
   PubMed Web of Science ®Google Scholar
• APA. Diagnostic and statistical manual of mental disorders, 4th edn., text rev Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams Janet BW. Struc- tured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; November 2002.
   Google Scholar
• Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision (ICD-9). http:/www.cdc.gov/nchs/icd/icd9.htm.
   Google Scholar
• Sos I, Kiss N, Csorba J, Gerevich J. Tizanidine in the treatment of acute withdrawal symptoms in heroin dependent patients. Orv Hetil 2000 Apr 9;141:783–786.
   Google Scholar
• Freye E, Levy JV, Partecke L. Use of gabapentin for attenuation of symptoms following rapid opiate medically supervised withdrawal (ROD)-correlation with neurophysiological parameters. Clin Neurophysiol 2004;34:81–89.
   Web of Science ®Google Scholar
• Martínez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:599–601.
   PubMed Web of Science ®Google Scholar
• Compton P, Kehoe P, Sinha K, Torrington MA, Ling W. Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend 2010;109:213–219.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Hopf FW, Diana M, Bonci A. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology 2012;37:163–177.
   PubMed Web of Science ®Google Scholar
• Salehi M, Kheirabadi GR, Maracy MR, Ranjkesh M. Importance of Gabapentin Dose in Treatment of Opioid Withdrawal. J Clin Psychopharmacol 2011;31:593Y596.
   Web of Science ®Google Scholar
• Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalized anxiety disorder. Cochrane Database Syst Rev 2010 Art. No.: CD006815 doi: 10.1002/14651858.CD006815.pub2.
   PubMed Web of Science ®Google Scholar
• Hauser L, Anupindi R, Moore W. Hydroxyzine for the treatment of acute opioid withdrawal: a clinical experience. Resid Staff Phys 2006;52:6.
   Google Scholar
• American Society of Addiction Medicine. National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. 2015.
   Google Scholar
• Kenne DR, Boros AP, Fischbein RL. Characteristics of opiate users leaving detoxification treatment against medical advice. J Addict Dis 2010 Jul;29:383–394.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Vital Signs: prescription Painkiller Overdoses July 2012. Available at: http://www.cdc.gov/vitalsigns/PainkillerOverdoses/index.html.
   Google Scholar
• Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA. The Combination Very Low-Dose Naltrexone–Clonidine in the Management of Opioid Withdrawal. Am J Drug and Alcohol Abuse 2012 May;38:200–205.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006;1:CD001333..
   Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; Apr 16:CD002207.
   Google Scholar
• Schwartz RP, Alexandre PK, Kelly SM, O’Grady KE, Gryczynski J, Jaffe JH. Interim versus standard methadone treatment: a benefit-cost analysis. J Subst Abuse Treat 2013; Mar:43:306–314.
   Google Scholar
• Mannelli P, Peindl K, Lee T, Bhatia KS, Wu LT. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev 2012;5:52–63.
   PubMedGoogle Scholar
• Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. Ann NY Acad Sci 2011;1216:144–166..
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013;108:1628–1637.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Wide-ranging On Line Data for Epidemiologic Research (WONDER). Compressed mortality file 2014. Available at: http://wonder.cdc.gov/mortsql.html.
   Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 2003;35:253–259.
   PubMed Web of Science ®Google Scholar
• Bisaga A et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. Journal of Substance Abuse Treatment 2014;46:546–552.
   PubMed Web of Science ®Google Scholar
• Smith, R et al. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016;111:1160–1174.
   PubMed Web of Science ®Google Scholar